Abstract
Smoking cigarettes represents a behavior that implies severe health risks the consumer is not able to anticipate with certainty. In contrast to most expert assessment, individual risk perceptions of consumers are distorted in many ways. Perceived risk is a complex and multidimensional hypothetical construct that captures the individual assessment of the potential consequences of product use. Since smoking cessation may not be achieved by all cigarette smokers, risk reduction represents a complementary strategy of contributing to public health by reducing adverse consequences of tobacco use. Innovative products that modify, or reduce, the risks of smoking (modified risk tobacco products, MRTPs) can be helpful and beneficial in this regard. For regulatory authorities evaluating MRTPs, the measurement of perceived risk of their usage compared to the perceived risk of other tobacco and nicotine-related products as well as cessation is of utmost importance. Since no currently available measurement instrument meets all necessary and desirable properties of comparable risk perception assessment, a new instrument, the Perceived Risk Instrument (PRI), capturing the domains of Perceived Health Risk and Perceived Addiction Risk, was developed. The PRI provides measures that are directly comparable across different tobacco and nicotine-related products, as well as subpopulations based on current smoking status. Furthermore, the PRI allows for assessing the perceived risk to the individual respondent (personal risk, PRI-P) and the perceived risk to the user of a product in general (general risk, PRI-G) on a comparable scale. The newly developed PRI is expected to advance tobacco research and to inform regulators in their decision making. The development of the instrument can also serve as a showcase for how complex constructs, such as risk perception in the field of tobacco products, can be measured.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50(2), 179–211.
Andrich, D. (1988). A general form of Rasch’s extended logistic model for partial credit scoring. Applied Measurement in Education, 1(4), 363–378.
Bandura, A. (1998). Health promotion from the perspective of social cognitive theory. Psychology and Health, 13(4), 623–649.
Beacher, F., Magnani, P., Ramazzotti, A., Weitkunat, R., Kallischnigg, G., Coleman, S., & Alfieri, T. (2016, March 2–5). Study to Quantitatively Assess Tobacco Heating System 2.2 potential messages. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) 2016 Annual Meeting, Chicago, USA.
Cano, S., & T. Salzberger (2017). Measuring risk perceptions. In G. Emilien, R. Weitkunat, & F. Lüdicke (Eds.), Consumer perception of product risks and benefits. Chapter II.3 (pp. XX–XX).
Cano, S., Chrea, C., Salzberger, T., Alfieri, T., Emilien, G., Mainy, N., Ramazzotti, A., Lüdicke, F., & Weitkunat, R. (2016). Development and validation of a new instrument to measure perceived risks associated with the use of tobacco and nicotine-containing products. Unpublished manuscript at the time of writing.
Festinger, L. (1957). A theory of cognitive dissonance. Stanford: Stanford University Press.
Fischer, G. H. (1995). Derivations of the Rasch model. In G. H. Fischer & I. W. Molenaar (Eds.), Rasch models (pp. 15–38). New York: Springer.
Fischer, A. R. H. (2017). Perception of product risks. In G. Emilien, R. Weitkunat, & F. Lüdicke (Eds.), Consumer perception of product risks and benefits. Chapter II.2 (pp. XX–XX).
Food and Drug Administration (FDA). (2009). Patient reported outcome measures: Use in medical product development to support labeling claims. Accessed May 19, 2016, from http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
Food and Drug Administration (FDA). (2012). Guidance for industry—modified risk tobacco product applications (draft guidance) [online]. Accessed May 19, 2016, from http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297751.pdf
Institute of Medicine. (2012). Scientific standards for studies on modified risk tobacco products. Washington, DC: The National Academies Press.
Kahneman, D., Slovic, P., & Tversky, A. (Eds.). (1982). Judgement under uncertainty: Heuristics and biases. New York: Cambridge University Press.
Rasch, G. (1960). Probabilistic models for some intelligence and attainment tests. Copenhagen: Danish Institute for Education Research (Expanded edition (1980) with foreword and afterword by B. D. Wright, Chicago: The University of Chicago Press, 1980. Reprinted Chicago: MESA Press, 1993).
Revicki, D. (2007). FDA Draft guidance and health-outcomes research. Lancet, 369, 540–542.
Royal College of Physicians. (2007). Harm reduction in nicotine addiction: Helping people who can’t quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. London: RCP.
Salzberger, T., Chrea, C., Cano, S., Martin, M., Emilien, G., Mainy, N., Ramazzotti, A., Weitkunat, R., & Lüdicke, F. (2016). Development of a conceptual framework of perceived risks associated with the use of tobacco and nicotine-containing products. Unpublished manuscript at the time of writing.
Scientific Advisory Committee of the Medical Outcomes Trust. (2002). Assessing health status and quality of life instruments: Attributes and review criteria. Quality of Life Research, 11, 193–205.
Slovic, P. (1987). The perception of risk. Science, 236(4799), 280–285.
Slovic, P. (2000). What does it mean to know a cumulative risk? Adolescents’ perceptions of short-term and long-term consequences of smoking. Journal of Behavioral Decision Making, 13(2), 259–266.
Slovic, P., Finucane, M. L., Peters, E., & MacGregor, D. G. (2004). Risk as analysis and risk as feelings: Some thoughts about affect, reason, risk, and rationality. Risk Analysis, 24(2), 311–322.
Stone, R. N., & Grønhaug, K. (1993). Perceived risk: Further considerations for the marketing discipline. European Journal of Marketing, 27(3), 39–50.
U.S. Department of Health and Human Services. (1990). The Health Benefits of Smoking Cessation. US Department of Health and Human Services Public Health Service Centers for Disease Control Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health 1990. DHHS Publication No. (CDC) 9O-8416.
Weinstein, N. D. (1989). Optimistic biases about personal risks. Science, 246(4935), 1232–1233.
Weinstein, N. D., Marcus, S., & Moser, R. (2005). Smokers’ unrealistic optimism about their risk. Tobacco Control, 14, 55–59.
Wellek, S., & Blettner, M. (2012). On the proper use of the crossover design in clinical trials: Part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int, 109(15), 276–281.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Salzberger, T., Cano, S. (2017). The Perception Risk Instrument (PRI). In: Emilien, G., Weitkunat, R., Lüdicke, F. (eds) Consumer Perception of Product Risks and Benefits. Springer, Cham. https://doi.org/10.1007/978-3-319-50530-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-319-50530-5_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-50528-2
Online ISBN: 978-3-319-50530-5
eBook Packages: Economics and FinanceEconomics and Finance (R0)